acute leukemia
Conditions
Interventions
1:Chidamide and descitabine plus interferon
Sponsors
Sichuan Academy of Medical Sciences Sichuan Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
7 Years to 59 Years
Inclusion criteria
Inclusion criteria: 1. Patient with acute leukemia treating by allo-HSCT; 2. MRD was detected re-positive and bone morrow test still CR after allo-HSCT.
Exclusion criteria
Exclusion criteria: 1. lactation, and unwilling to use contraception childbearing age woman; 2. patient with history of clinical significant extended QTc interval; Patients with ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI) attack within 1 year, congestive heart failure (CHF), and symptomatic coronary heart disease requiring medication; 3. Ultrasound B showed that the width of the fluid dark region of the pericardial lumen at the end of diastolic period was >=10mm; 4. Receive an organ transplant; 5. In the 7 days before enrollment, received symptomatic treatment against the previous bone marrow toxicity; 6. With active hemorrhage; 7. With disease or history of thrombus, embolism, cerebral hemorrhage, cerebral infarction, etc.; 8. Active infection, or fever that persists for 14 days prior to enrollment; 9. With HBV, HCV, HIV active infection; 10. No more than 6 weeks after main organ surgery; 11. Liver, renal function abnormal; 12. Mental disorder; unable to obtain a informed consent; 13. Drug and long-term alcohol abuse may affect the evaluation of the experimental results; 14. Leukemia infects the central nervous system; 15. Investigator judges those not suitable for involving.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ????;??;??; | — |
Countries
China
Contacts
Public ContactHuang Xiaobing
Sichuan Academy of Medical Sciences Sichuan Provincial People's Hospital
Outcome results
None listed